Head and neck squamous cell carcinoma (HNSCC) represents a group of tumors arising in
the oral cavity, oropharynx, and larynx. Although HNSCC is traditionally associated with …

Over the past 10 years, cancer immunotherapy has made significant progress in multiple
cancer types and has been gradually been applied to clinical cancer care, in which the …

Background To evaluate potential synergistic effect of pembrolizumab with radiotherapy
(RT) compared with a standard-of-care (SOC) cetuximab–RT in patients with locally …

Background Programmed death-ligand 1 (PD-L1) is an immune checkpoint that is primarily
located on the surface of tumor cells. PD-L1 expression detected by immunohistochemistry …

Laryngeal carcinoma is the second common malignancy of the upper aerodigestive tract
after lung cancer; in most cases is a squamous cell carcinoma, whose risk factors include …

The expression of programmed cell death-ligand 1 (PD-L1) is being used as a predictive
biomarker for immunotherapy in head and neck squamous cell carcinoma (HNSCC). Our …

Head and neck cancer has high heterogeneity with poor prognosis, and emerging
researches have been focusing on the prognostic markers of head and neck cancer. PD-L1 …

Background Fulfilling the promise of cancer immunotherapy requires novel predictive
biomarkers to characterise the host immune microenvironment. Deciphering the complexity …

Immunotherapy has been recently approved for the treatment of relapsed and metastatic
human papilloma virus (HPV) positive and negative head and neck squamous cell …

Background Cancer cells induce the infiltration of various immune cells that are located or
distributed in different sites and play multiple roles, which have recently been proposed to …